Equity Profile

PODD

Insulet Corporation

Health CareHealth Care Equipment$10.6B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Insulet Corporation (PODD) is a healthcare company that specializes in developing and manufacturing innovative insulin delivery systems for people with diabetes. With a market cap of $11 billion, Insulet is at the forefront of the healthcare equipment industry, focusing on improving patient outcomes through advanced technology.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and attract more customers, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, surpassing estimates by 24.78%. However, the stock dropped 9.70% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Focus on expanding product offerings in insulin delivery.
Commitment to enhancing customer support services.
Plans to invest in research and development for innovative diabetes solutions.

Expectations

Wall Street Expectations

Overall, analysts are cautious as there are no available estimates for this quarter, leaving investors uncertain about future performance.

Bull Case

If Insulet continues its trend of beating EPS estimates, it could signal strong demand for its products and lead to positive market sentiment.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant downward pressure on the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and a strong performance could reassure investors about the company's growth trajectory.

How is Insulet addressing competitive pressures in the insulin delivery market?

Understanding the company's strategy in a competitive landscape will be vital for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Insulet's ability to innovate and capture market share, especially given recent advancements in diabetes management technology.

Supporting Evidence

Insulet has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a positive surprise.

Recent product launches have received positive feedback, suggesting strong consumer demand.

Key Risk

If the company reports an EPS below $1.20, it could undermine the bullish sentiment surrounding its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around Insulet's ability to maintain growth in a competitive market while managing costs effectively.

Bull Confirmed If

EPS growth of at least 20% year-over-year would confirm strong demand and operational efficiency.

Bear Confirmed If

Any EPS below $1.20 could raise concerns about market share and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests a potential average 1-day move of +1.90%, confirming strong demand and growth.

In-Line / Cautious

If results are in line, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline, with history suggesting an average 1-day move of +1.09% when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any changes in guidance regarding revenue growth for the upcoming quarters.
3Details on competitive strategies in the insulin delivery space.
4Insights into customer acquisition and retention rates.
5Management's outlook on the overall diabetes care market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and attract more customers, which is crucial for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

PODD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+9.35%

Avg Stock Reaction

+1.69%

Last Quarter Recap

In Q1-2026, Insulet reported an EPS of $1.42, surpassing estimates by 24.78%. However, the stock dropped 9.70% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Focus on expanding product offerings in insulin delivery.
Commitment to enhancing customer support services.
Plans to invest in research and development for innovative diabetes solutions.

Expectations

Wall Street Expectations

Overall, analysts are cautious as there are no available estimates for this quarter, leaving investors uncertain about future performance.

Bull Case

If Insulet continues its trend of beating EPS estimates, it could signal strong demand for its products and lead to positive market sentiment.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to significant downward pressure on the stock.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

EPS is a critical measure of profitability, and a strong performance could reassure investors about the company's growth trajectory.

How is Insulet addressing competitive pressures in the insulin delivery market?

Understanding the company's strategy in a competitive landscape will be vital for assessing future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating Insulet's ability to innovate and capture market share, especially given recent advancements in diabetes management technology.

Supporting Evidence

Insulet has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a positive surprise.

Recent product launches have received positive feedback, suggesting strong consumer demand.

Key Risk

If the company reports an EPS below $1.20, it could undermine the bullish sentiment surrounding its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around Insulet's ability to maintain growth in a competitive market while managing costs effectively.

Bull Confirmed If

EPS growth of at least 20% year-over-year would confirm strong demand and operational efficiency.

Bear Confirmed If

Any EPS below $1.20 could raise concerns about market share and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±21.46%

Historical Avg

±4.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±21.5% while PODD has averaged ±4.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

65.5%

Calls (14K)P/C Ratio: 1.72Puts (273K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Insulet beats expectations, history suggests a potential average 1-day move of +1.90%, confirming strong demand and growth.

In-Line / Cautious

If results are in line, the stock may experience muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline, with history suggesting an average 1-day move of +1.09% when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their market reception.
2Any changes in guidance regarding revenue growth for the upcoming quarters.
3Details on competitive strategies in the insulin delivery space.
4Insights into customer acquisition and retention rates.
5Management's outlook on the overall diabetes care market.